267226-07-3

Upstream product

• 217302-87-9 2-(4-benzyloxyphenyl)-1-ethylindolizine 
• 4254-67-5 2-bromo-1-(4-benzyloxyphenyl)-1-ethanone 
• 622-39-9 2-propylpyridine 
• 267226-06-2 3-(4-benzyloxy-phenyl)-4-ethyl-pyrrolo[2,1,5-cd]indolizine-1,2-dicarboxylic acid dimethyl ester 

Downstream Products

• 217318-90-6 NNC 45-0095 
• 267226-08-4 2-(4-benzyloxy-phenyl)-1-ethyl-pyrrolo[2,1,5-cd]indolizine 

Relevant academic research and scientific papers

Synthesis and pharmacology of a novel pyrrolo[2,1,5-cd] indolizine (NNC 45-0095), a high affinity non-steroidal agonist for the estrogen receptor

1-Ethyl-2-(4-hydroxyphenyl)pyrrolo[2,1,5-cd]indolizine (NNC 45-0095) is a novel compound which represents the parent pharmacophore structure of a series of pyrrolo[2,1,5-cd]indolizine derivatives with mixed estrogen agonist/antagonist properties. NNC 45-0095 binds with high affinity to the estrogen receptor (IC50 = 9.5 nM) and exhibits full protection of bone loss in the ovariectomized mouse model for post-menopausal osteoporosis. (C) 2000 Elsevier Science Ltd. All rights reserved.

Synthesis and estrogen receptor binding affinities of novel pyrrolo[2,1,5-cd]indolizine derivatives

A series of pyrrolo[2,1,5-cd]indolizine derivatives has been synthesized and evaluated as ligands for the estrogen receptor. Properly substituted mono- and di-hydroxy derivatives showed binding in the low nanomolar range in accordance with their structural resemblance to estrogen. (C) 2000 Elsevier Science Ltd.